Suberoylanilide hydroxamic acid (SAHA), the first HDAC inhibitor approved for cancer therapy, has been demonstrated to protect against dopaminergic degeneration by enhancing the release of neurotrophic factors from astrocytes [152]. Here, HDAC9 is linked to cancer.